Study of PF-08634404 with Chemotherapy Compared to Atezolizumab Plus Chemotherapy in Adults with Extensive-Stage Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating a new medicine called PF-08634404 combined with chemotherapy in adults with extensive-stage small cell lung cancer ES-SCLC, a fast-growing type of lung cancer that has spread widely. The study aims to learn how well PF-08634404 works when given with chemotherapy compared to an approved treatment called atezolizumab plus chemotherapy. The study is conducted in two phases to assess safety, tolerability, and effectiveness of the treatments. Participants will receive treatments through intravenous IV infusions in repeated cycles. In the first phase, the focus is on safety and tolerability of PF-08634404 with chemotherapy. The second phase compares PF-08634404 plus chemotherapy to atezolizumab plus chemotherapy. Some participants may continue receiving PF-08634404 alone after the initial combination treatment. Treatments are delivered as IV infusions during scheduled cycles. During the study, participants will undergo medical tests to monitor their health and cancer status. Researchers will assess response rates, survival times, progression-free survival, and quality of life using standard measurement criteria. Safety will be closely monitored through tracking adverse events and laboratory tests. The study lasts up to around two years after the last participant completes treatment, with regular visits for assessments and follow-up.

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer